You are subscribed to the Drug Topics Community Pharmacists' Report. Unsubscribe here.

Drug Topics Community Pharmacists' Report

Print Subscribe

Digital Edition Subscribe

November 6, 2012

Web Version  |  Digital Edition  |  Share with a colleague

Facebook Like   Twitter Tweet

Top article

DT Blog: Balancing customer service and patient care

The United States may be the world's last bastion of customer service. Inherent in our national psyche is the expectation that when we pull out our wallets to purchase something, whether a product or a service, we have a right to satisfaction. All retailers wishing to succeed in the United States must understand this.
» More

Continuing Education

New CPE Series: October activity available now

Welcome to the second activity of our new CPE series: Medication Therapy Management (MTM) in Patients with Diabetes, which has been designed for pharmacists who take care of patients with diabetes. You can earn up to 14 CPE credits from September 2012-March 2013 with 7 monthly knowledge-based activities. The October activity will cover medical nutrition therapy, physical activity, and health maintenance considerations for patients with diabetes.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login.

Announcement: Welcome to the new user registration process. This new process requires all pharmacists and pharmacy technicians to provide or update their NABP e-Profile ID in order to electronically keep track of CPE credits from ACPE-accredited providers. If you have not done so, you can obtain your NABP e-Profile ID now at www.MyCPEmonitor.net. This profile will enable you to have one login for all the NABP programs and services you will need throughout your career.

Today's Headlines

VALID Compounding Act introduced Nov. 2

Congressman Edward J. Markey (D-Mass.) introduced legislation Nov. 2 that he believes will strengthen FDA's authority to oversee compounding pharmacies. » More

FDA expands use of rivaroxaban for DVT, PE

FDA has expanded the approved use of oral anticoagulant rivaroxaban (Xarelto, Janssen) to include three new indications: treatment of deep vein thrombosis, treatment of pulmonary embolism, and reducing the risk of recurrent DVT and PE following initial treatment. » More

TAKE OUR SURVEY

Rep. Edward Markey (D-Mass.) introduced new legislation that he believes will strengthen FDA's oversight of compounding pharmacies (see third story above.) Do you believe that the VALID Compounding Act will do that?

- Yes
- No

Click Here to let us know.

 

Subscribe Now!

You must click here to continue receiving the Drug Topics Community Pharmacists' Report

Advertisement

Check these out, too

Anticoagulants show similar bleeding rates

Two NECC products tainted with bacteria

Recall: Infusion pump has bad touchscreen

Aging comes with a high cost for Rx treatments

Voices

Anticoagulation Update

JP at Large: Pharmacists are Job 1

View from the Zoo: Feeling like a real pharmacist

Viewpoints: Guest columnists' commentary

Regulatory and Legal: News and analysis

Meetings and Events

 
Powered by Modern Medicine Advanstar Medical Communications Group